Login / Signup

Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Dennis A EichenauerHorst MüllerLeonard ElgerHelen GoergenMichael FuchsStefanie KreisslBoris BöllVolker DiehlBastian von TresckowPeter BorchmannAndreas Engert
Published in: British journal of haematology (2021)
Data on non-Hodgkin lymphoma (NHL) after classical Hodgkin lymphoma (cHL) are scarce. We therefore performed a retrospective analysis comprising 11·841 cHL patients who had first-line treatment within the randomized German Hodgkin Study Group (GHSG) HD7-HD15 studies. After a median follow-up of 106 months, 175 patients (1·5%) had developed NHL. The median time to NHL was 44 months, the median age at NHL diagnosis was 54 years. The five-year event-free survival and overall survival estimates from the diagnosis of NHL were 36·9% and 44·2%, respectively. Thus, NHL after cHL is a rare event primarily affecting older individuals and often resulting in the patient´s death.
Keyphrases
  • hodgkin lymphoma
  • free survival
  • newly diagnosed
  • clinical trial
  • randomized controlled trial
  • ejection fraction
  • physical activity
  • open label
  • double blind
  • deep learning
  • phase iii
  • community dwelling